INTRODUCTION
Vancomycin is a bactericidal glycopeptide antibiotic widely used in children for treating methicillin-resistant Staphylococcus aureus (MRSA) infections [1] . In fact, vancomycin trough serum concentrations between 10 and 15 lg/mL have been recommended for serious infections caused by MRSA (including endocarditis, osteomyelitis, meningitis, and pneumonia) [2, 3] . Although this consensus statement excluded recommendations for children, aggressive vancomycin dosing regimens are nonetheless being used with pediatric patients. This dosing may increase the incidence of nephrotoxicity in children.
Vancomycin-associated renal toxicity has been a point of controversy since 1958, when Geraci et al. [4] published the first case series linking to nephrotoxic effects of vancomycin. Since then, several studies have reported an association between vancomycin serum trough concentrations and renal toxicity [5] [6] [7] .
Although vancomycin has been associated with nephrotoxicity, causality has not been firmly established. Data in adult patients indicate that higher vancomycin doses (or higher serum trough concentrations) are associated with increased nephrotoxicity [8] [9] [10] . Nephrotoxicity data associated with higher vancomycin trough attainment through aggressive dosing in the pediatric population are lacking, although nephrotoxicity incidence rates might be higher with increased troughs, as evident in adults.
However, the definition of renal toxicity, as well as the patient population and disease severity, has varied among these studies.
Therefore, the authors performed a retrospective, observational clinical study with the main goal of determining the overall incidence rate and predisposing factors associated with development of nephrotoxicity in children receiving vancomycin, including those achieving high average vancomycin serum trough concentrations of C10 lg/mL.
METHODS

Study Setting
This study was conducted at Dammam 
Inclusion and Exclusion Criteria
In the present retrospective study, eligible pediatric patients were C1 week old (and not born prematurely before 37 weeks gestational age) to B15 years of age; had received vancomycin for at least 48 h between October 2010 and September 2012, and had normal baseline SCr values (defined as B0.6 mg/dL for patients B1 month old and B0.9 mg/dL for those [1 month old). increase from baseline in SCr based on serial SCr measurements over 2 days [8, 9] . Baseline SCr and age-and sex-adjusted creatinine clearance calculations were made before administration of vancomycin in all patients, using the following formula [10] : Estimated creatinine clearance = (140 -age) (weight in kg)/ (72 9 serum creatinine) 9 0.085 (women only).
Grouping of the Studied Patients
An average vancomycin trough level was calculated using all measured serum concentration results throughout therapy.
Baseline vancomycin clearance (L/h) was obtained from pharmacokinetic values from the first steady-state vancomycin concentration, using the population volume of distribution. High trough therapy was defined as an average serum trough concentration of C10 lg/mL and low trough therapy as an average serum trough concentration of \10 lg/mL for all concentrations throughout therapy.
Statistical Analysis
All comparisons were unpaired, and all tests of significance were two-tailed. Continuous variables were compared using the Student t test for normally distributed variables, and the Mann-Whitney U test for non-normally distributed variables. The Chi-square test was used to compare categoric variables. The primary data analysis compared patients who met the study definition for renal toxicity with those who did not. Values were expressed as mean (±SD) for continuous variables and as a percentage of the group from which they were Table 1 shows the demographic and clinical data characteristics of the studied pediatric cases receiving vancomycin therapy. The total number of cases was 265, of which 130 were male. Gender factor had no clinically significant difference between high and low trough vancomycin levels. Some parameters in the studied table showed a significant difference when comparing a low vancomycin trough level \10 lg/mL with a high vancomycin level C10 lg/mL; these were mean age (P[0.030), meningitis (P[0.026), dermal infectious status (P[0.031), mean initial (P = 0.001) and overall (P = 0.032) vancomycin dosage, and frequency of ICU admitted cases (P = 0.041). Other parameters showed a non-significant difference when comparing a low vancomycin trough level \10 lg/mL with a high vancomycin level C10 lg/mL; these were bacteremia, pneumonia, myocarditis, arthritis, endocarditis, malignancy, former prematurity, congenital heart disease, respiratory disease, and respiratory distress syndrome. Table 2 Using multiple regression analysis, cases admitted to the ICU and to whom aminoglycoside medication was administered concurrently with vancomycin medication showed a significant high renal toxicity incidence [odds ratio (OR) 2.91; 95% confidence interval (CI) 1.70, 8.61; P value \0.03)] and (OR 9.11; 95% CI 4.11, 24.13; P\0.05), respectively. terminology applied in the current study followed that in many documented references [8] [9] [10] as previously mentioned.
RESULTS
In the studied literature, the incidence of renal failure in adult patients treated with vancomycin ranged from 12% to 42%, and [12, 13] .
In the present study, 27.2% of the studied children suffered from renal toxicity during vancomycin therapy, and the incidence of renal toxicity increased when the vancomycin trough level became [10-15 lg/mL (41%) and reached its peak in 87.5% of cases with serum trough vancomycin levels of [15 lg/mL. In accordance with the presented figures, several adult and pediatric studies documented the previously noted information [8, 14] .
In the present study, other factors have been reported that can affect the incidence of occurrence of renal toxicity beside the vancomycin serum level. These include duration of vancomycin therapy, concomitant usage of aminoglycosides, ICU admission status, presence of bacterial meningitis, presence of bacterial dermal infection, age, and weight of the studied pediatric cases.
In the present study of 72 cases suffering from renal toxicity, there were 38 pediatric cases who were given aminoglycosides as well as vancomycin therapy. About one-third (37.4%) of the studied pediatric cases with high vancomycin trough levels were admitted to the ICU. The studied pediatric cases with high vancomycin trough levels of C10 lg/dL were associated with high mean overall vancomycin dose (41.2 mg/kg/d) when compared with low trough level \10 lg/mL (32.2 mg/kg/d), with a significant difference (P = 0.032). In accordance with the present results, one study of adult cases found a significant nephrotoxicity percentage among patients receiving a high dose of vancomycin therapy and who were admitted to the ICU [15] .
In the present study, most of the pediatric cases suffering from nephrotoxicity induced by vancomycin therapy were associated with a significant increasing SCr level that returned to the average baseline concentration at the end of therapy or hospital discharge. In accordance with the present findings, one study by Jeffries et al. [9] stated that 72% of the studied cases of patients suffering from vancomycin-induced nephrotoxicity had a high creatinine level that returned to baseline at the time of hospital discharge.
Regarding the time of occurrence of vancomycin-induced renal toxicity, several studies reported that the onset of renal toxicity mainly occurs after a lapse of 1-3 weeks from the onset of vancomycin therapy in adult patients [2, 9, 10] . In the present study, the time of occurrence of renal toxicity occurred in the first week for renal toxicity associated with both high and low trough vancomycin levels.
The duration of vancomycin therapy plays an important role in the induction of vancomycin-induced nephrotoxicity. Hidayat et al. [2] stated that increasing the duration of vancomycin therapy was associated with an increase in the incidence of occurrence of renal toxicity, and approximately 30% of the studied cases associated with nephrotoxicity were patients receiving vancomycin therapy for more than 14 days, while it was only 6.3% in adult patients receiving vancomycin therapy for less than 1 week.
CONCLUSION
The present work discussed the impact of vancomycin therapy in the renal function of the pediatric population. The result of this study showed that vancomycin-induced renal toxicity existed in 27.2% of the studied cases, and the incidence of renal toxicity was significantly increased with high trough vancomycin levels of C10 lg/mL. Admission to the ICU, prolongation of vancomycin therapy, and concurrent administration of other aminoglycoside medications during vancomycin therapy increased the incidence of renal toxicity in pediatric studied cases. In conclusion, renal functions tests and continuous monitoring of vancomycin trough levels for children receiving vancomycin therapy, especially admitted to the ICU and given other aminoglycoside medications, are essential.
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